Nowadays, the pharmaceutical and healthcare industries’ main challenges in the CIS countries and Eastern Europe include intense competition in the markets, increasing sophistication among consumer choices, and major changes in public policy/regulatory environments. Proliferation of generic drugs, the expiration of many proprietary drug patents, and longer and more expensive drug discovery cycles make it harder to maintain product and pricing power in changing environments where differentiation points are declining. Industry players experience falling profit margins and the markets see increasing fragmentation.
We help firms in adapting their practices to the changing industry climate and spot new opportunities. Specific areas of our expertise include formulation and help in implementing winning strategies for new products, insights on new consumer segments and new markets, customized help in sourcing intermediate/long-term finance, and helping the client to get a better understanding of the ways to exploit profitable production opportunities in emerging markets.